Covid-19 vaccination in patients with multiple myeloma: Focus on immune response
Heinz Ludwig 1 , Jesús San-Miguel 2 , Nikhil Munshi 3 , Pieter Sonneveld 4 , María-Victoria Mateos 5 , Philippe Moreau 6 , Evangelos Terpos 7
Patients with multiple myeloma (MM) are at increased risk for severe clinical symptoms and mortality due to SARS-CoV-2 infection.
To protect against these complications, the International Myeloma Society recommends vaccinating all patients with monoclonal gammopathy of undetermined significance (MGUS), monoclonal gammopathies of clinical significance, smoldering MM (SMM), and MM.1 Protective immunity against SARS-CoV2 in those patients is partially relevant given their increased risk for infections, which may cause significant morbidity and represent the second most frequent cause of mortality.2
The extent of the immune impairment in MM largely depends on the disease-inherent immune suppression exerted by the malignant clone that can affect all immune effector mechanism including B cells, T cells, NK cell, and dendritic cells, and the complement system.3, 4
The myeloma-induced immune deficiency can resolve completely during periods of deep response, such as minimal residual disease negativity, but deep responses are achieved in a proportion of patients only, and several of those eventually relapse and become immune suppressed again and/or suffer from other causes of reduced immune competence.
Many patients present at older age with comorbidities and immunosenescence5 with an impaired defense against infections and compromised development of long-term immune memory, which is aimed at by vaccination. Myeloma therapy including proteasome inhibitors, dexamethasone, high dose melphalan, monoclonal antibodies, antibody-drug conjugates, BiTEs and cellular therapies, such as CAR-T cells, result in specific and cumulative immune suppression, and after extensive therapy in T cell exhaustion.6
Hence, myeloma and myeloma treatment-induced immunosuppression and other above mentioned factors frequently impose critical hurdles for an effective vaccination response in many patients and emerging data seem to underpin these concerns.7
CITATION Am J Hematol. 2021 Aug 1;96(8):896-900.